# Amycretin

Canonical source: https://retacompare.com/encyclopedia/amycretin

Single peptide that activates both the amylin and GLP-1 receptor families.

Reference facts

Also known asNN1213, Amylin/GLP-1 unimolecularCategoryGLP-1 & MetabolicMechanism of actionSingle peptide that activates both the amylin and GLP-1 receptor families.TargetsGLP-1R, Amylin receptorsIndications under research or approvedObesityRegulatory status (reference entry)Investigational (Phase 2 oral, Phase 1b subcutaneous)Half-life~7 days (subcutaneous formulation)Sequence notesUnimolecular dual amylin and GLP-1 receptor agonist; full sequence not publicly disclosed.Originator / sponsorNovo NordiskFirst reported2024
    Primary References

Amycretin Phase 1 oral, Lancet 2025


    Explore research articles about Amycretin


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Amycretin Phase 1 oral, Lancet 2025: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00099-7/fulltext